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OBJECTIVE—b-Cell turnover and its potential to permit b-cell
regeneration in adult primates are unknown. Our aims were 1)t o
measure b-cell turnover in adult nonhuman primates; 2) to estab-
lish the relative contribution of b-cell replication and formation of
new b-cells from other precursors (deﬁned thus as b-cell neogen-
esis); and 3) to establish whether there is an adaptive increase in
b-cell formation (attempted regeneration) in streptozotocin (STZ)-
induced diabetes in adult nonhuman primates.
RESEARCH DESIGN AND METHODS—Adult (aged 7 years)
vervet monkeys were administered STZ (45–55 mg/kg, n =7 )o r
saline (n = 9). Pancreas was obtained from each animal twice,
ﬁrst by open surgical biopsy and then by euthanasia. b-Cell turn-
over was evaluated by applying a mathematic model to measured
replication and apoptosis rates.
RESULTS—b-Cell turnover is present in adult nonhuman pri-
mates (3.3 6 0.9 mg/month), mostly (;80%) derived from b-cell
neogenesis. b-Cell formation was minimal in STZ-induced diabe-
tes. Despite marked hyperglycemia, b-cell apoptosis was not in-
creased in monkeys administered STZ.
CONCLUSIONS—There is ongoing b-cell turnover in adult non-
human primates that cannot be accounted for by b-cell replica-
tion. There is no evidence of b-cell regeneration in monkeys
administered STZ. Hyperglycemia does not induce b-cell apopto-
sis in nonhuman primates in vivo. Diabetes 60:848–856, 2011
I
n health, the number of b-cells (collectively referred
to as the “b-cell mass”) is sufﬁcient to permit the
required rate of basal and meal-stimulated insulin
secretion to maintain glycemic control. Both type 1
and 2 diabetes are characterized by deﬁcit of b-cell mass
and insufﬁcient insulin secretion (1–6). Type 1 and 2 di-
abetes can be effectively treated by restoring b-cell mass
through pancreas transplantation (7,8). However, because
of the limited availability of donor organs and the adverse
effects of long-term immunosuppression, alternative strat-
egies to reverse the deﬁcit in b-cell mass in diabetes are
required. One such strategy is to foster restoration of
b-cells from putative endogenous sources.
Complete or partial reversal of diabetes by b-cell re-
generation has been reported in rodents under several
conditions. An acute deﬁcit in b-cell mass induced by the
b-cell toxin streptozotocin (STZ) in newborn rats is fol-
lowed by recovery of b-cell mass (9). However, neither
glucose intolerance nor diabetes induced by a partial
pancreatectomy in adult humans or dogs resolves spon-
taneously (10–14). Likewise, diabetes due to a b-cell deﬁcit
induced by a b-cell toxin in nonhuman primates or pigs
does not resolve spontaneously (15,16). The differences in
the observed potential for b-cell regeneration in juvenile
rodents and adult humans are likely due to the age of study
subjects because adult rodents have also been shown to
have a much reduced capacity for b-cell regeneration (17).
The current study sought to establish 1) whether b-cell
turnover is present in adult nonhuman primates, and if so
to quantify its rate; 2) whether the primary source of new
b-cell formation in adult nonhuman primates is replication
of existing b-cells or formation of new b-cells indepen-
dently of b-cell replication (deﬁned thus as b-cell neo-
genesis); and 3) whether there is any evidence of an
adaptive increase in b-cell formation (regeneration) in an
STZ model of type 1 diabetes in nonhuman primates.
RESEARCH DESIGN AND METHODS
Study design. b-Cell turnover was quantiﬁed by a recently developed model
(18). If b-cell mass and b-cell turnover are at nonsteady state, this model
requires measurement of b-cell mass, b-cell replication, and b-cell apoptosis at
multiple different time points. Alternatively if b-cell mass and b-cell turnover
are at steady state, then a single time point is sufﬁcient.
To ensure steady state, we obtained pancreas ﬁrst by an open surgical
biopsy and then subsequently at euthanasia from each study animal. The ﬁrst
surgical sample was obtained 1 month after administration of STZ (n =7 )o r
saline (n = 9), and the second euthanasia sample was obtained between 2 and
6 months later as shown in Fig. 1.
Study animals. All procedures involving animals were conducted in compli-
ance with state and federal laws, standards of the U.S. Department of Health
and Human Services, and guidelines established by the Institutional Animal
Care and Use Committee at Wake Forest University. Sixteen male vervet
monkeys (Chlorocebus aethiops, 7.1 6 0.4 years) were obtained from a mul-
tigenerational pedigreed colony at University of California Los Angeles Vervet
Research Colony and transported to the animal facility of Wake Forest Uni-
versity. All monkeys were fed a standard chow diet (LabDiet 5037, Purina
LabDiet, Richmond, IN) and acclimatized to place and staff before study. The
animals were randomly divided into a control group (n = 9) and a group ad-
ministered STZ (n = 7) (Table 1).
Throughout the study period, body weight and an overnight-fasted blood
sample were procured monthly after sedation with ketamine (10–15 mg/kg i.m.,
Ketaset, Fort Dodge Animal Health, Fort Dodge, IA). The blood sample was
processed for measurement of plasma glucose, insulin and C-peptide con-
centrations, and HbA1c. Plasma glucose (Sigma-Aldrich, St. Louis, MO) was
assessed by enzymatic colorimetric methods. The inter- and intra-assay
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ORIGINAL ARTICLEcoefﬁcients of variation % are ,5% for glucose. Insulin and C-peptide were
determined using ELISA (Mercodia, Uppsala, Sweden), with inter- and intra-
assay coefﬁcients of variation ,10%. HbA1c was measured by high-performance
liquid chromatography (Primus PDQ, Primus Diagnostic, Kansas City, MO).
Induction of diabetes. To induce diabetes, monkeys were given a single dose
of STZ (45–55 mg/kg i.v., Zanosar, SICOR Pharmaceutics, Irvine, CA) under
sedation with ketamine. Control animals were manipulated similarly and given
similar injections (~0.3 mL) of saline rather than STZ. Plasma glucose was
measured 24 and 48 h after the treatment. All monkeys given STZ developed
fasting hyperglycemia (.144 mg/dL) within 48 h.
After induction of diabetes, postprandial glucose concentrations were
maintained in the range of 300–400 mg/dL by twice daily insulin injections (70%
intermediate-acting [e.g., NPH], 30% short-acting [e.g., regular] insulin, Novolin
70/30, Novo Nordisk USA, Princeton, NJ). The dose of insulin was adjusted
according to biweekly postprandial whole blood glucose measurements
obtained by a tail stick of nonsedated animals and measured by a glucometer.
Daily exogenous insulin requirements in the STZ group were 15.6 6 2.4 units
(range 7–23 units). Control monkeys were treated with 0.2 mL of saline
injected subcutaneously twice daily at the same time as diabetic monkeys
received insulin.
Pancreas computed tomography scans. To determine pancreas parenchy-
mal volume, abdominal computed tomography (CT) scans were performed at
baseline, 1 month after treatment (before pancreas biopsy), and before eu-
thanasia. After induction of anesthesia (as above), an orogastric tube was
placed and 20–50 mL of water was infused into the stomach to aid in outlining
the pyloric region. CT scans were taken by a Toshiba 32 Scanner with a helical
pitch of 27 (Toshiba, Tokyo, Japan). The parameters included 0.5 mm colli-
mation, ;120 kVp, and 300 mA based on a 7–8 kg monkey with an abdominal
depth of 12 cm. A 180-degree scan ﬁeld of view using small focus was set, and
a whole monkey scout was taken in the supine position to ensure correct
positioning. Scans were taken pre- and postcontrast (iopromide at 2 mL/kg
injected at 2 mL/s into the saphenous vein via a temporary indwelling cathe-
ter). Scout scans were taken before contrast, with a 10–15 s delay from in-
jection initiation before starting the postcontrast scan for capture of the later
arterial phase at the level of the abdominal slices. A second scan was initiated
;8 s from the completion of the ﬁrst scan to repeat the images of the abdomen
at 1 min, which represent delayed-enhancement postcontrast. The contiguous
0.5-mm axial images of delayed-enhancement postcontrast CT scans were
transferred to a PC workstation and analyzed using Vitrea 2 software (version
3.5, Vital Images, Minnetonka, MN). All images were analyzed at a window
level of 40 Hounsﬁeld units (HU) and window width of 300 HU. Pancreas was
identiﬁed and hand-outlined on the basis of the typical landmarks (splenic
vein, superior mesenteric artery). Then the total and parenchymal pancreas
area (cm
2) on each image was computed as previously described (19). Pan-
creas volume per section was calculated as the product of each pancreas area
and the CT section thickness. Total and parenchymal volumes of pancreas
were computed by summing the volume from each section that included
a piece of pancreas tissue.
Both the total and parenchymal pancreas volumes were comparable in
controls and monkeys given STZ (total pancreas 6.9 6 0.7 vs. 6.5 6 0.6 cm
3
controls vs. STZ; parenchymal pancreas 5.4 6 0.5 vs. 5.2 6 0.5 cm
3 controls vs.
STZ) (Table 1). The mean pancreas parenchymal volume of the three mea-
surements in each monkey was used to calculate b-cell mass. The total and
parenchymal pancreas volumes were ;30 and ;45% lower than the pancreas
weight measured at euthanasia (6.7 6 0.4, 5.3 6 0.3 cm
3, and 9.4 6 0.5 g,
respectively, assuming 1 cm
3 = 1 g), consistent with ﬁndings in humans (19),
most likely because of the impossibility of removing all fat from the pancreas
by dissection (fat extends into interlobular areas). Nonetheless, the mean
pancreas parenchymal volume in each monkey correlated with total pancreas
weight (r
2 =0 . 8 2 ,P , 0.0001, Fig. 2).
Intravenous glucose tolerance test. To assess b-cell function, an in-
travenous glucose tolerance test (IVGTT) was performed at baseline, 1 month
after treatment (before pancreas biopsy), and immediately before euthanasia.
Animals were sedated with ketamine (10–15 mg/kg i.m.) after an overnight
fast. After baseline blood sampling, 1.5 mL/kg of 50% dextrose was adminis-
tered via a butterﬂy catheter in a peripheral vein (saphenous vein commonly
chosen). Blood was sampled at 25, 0, 5, 10, 20, 30, and 60 min for analysis of
plasma glucose, insulin, and C-peptide concentrations in the baseline study,
whereas the IVGTTs before biopsy and euthanasia were followed by 67 mg/kg
of arginine infused over 30 s after the 30-min sample, and the sampling grid
was 25, 0, 5, 10, 20, 25, 30, 31, 33, 35, 37, and 40 min.
b-Cell function and insulin sensitivity. To assess b-cell function, the
minimal model (20) was applied to IVGTT samples collected 0–30 min after
glucose bolus injection, i.e., before the arginine stimulus. In detail, b-cell
function was evaluated by applying the minimal model of C-peptide secretion
and kinetics (21). Because no information is available on C-peptide kinetics in
vervet monkeys, the parameters of C-peptide kinetics were ﬁxed to values
provided by Van Cauter et al. (22). Indexes of responsivity to glucose of ﬁrst
phase, F1 (10
29), second phase, F2 (min
21 10
29), and basal secretion,
Fb (min
21 10
29) were quantiﬁed. To evaluate insulin sensitivity, SI (min
21 per
pmol/L), and glucose effectiveness, SG (min
21), the glucose minimal model
(23) was applied. Because glucose concentration exceeded the renal excretion
threshold in monkeys given STZ, a glucose minimal model was integrated with
the glucose kidney excretion model (24), with glomerular ﬁltration rate, ke1
(min
21), and renal threshold of glucose, ke2 (mg/dL), ﬁxed to human pop-
ulation values (i.e., ke1 = 0.0005 min
21 in controls and ke1 = 0.000676 min
21 in
monkeys given STZ; ke2 = 180 mg/dL both in controls and in monkeys given
STZ) (25).
Pancreas biopsy. After an overnight fast, monkeys were sedated with keta-
mine (10–15 mg/kg i.m.) and atropine (0.04 mg/kg, AtroJect SA, IVX Animal
Health Inc., St. Joseph, MO) and then intubated and anesthetized with iso-
ﬂurane gas (IsoFlo, Abbott Laboratories, North Chicago, IL). The monkeys
that received STZ were given regular insulin (Novolin R, Novo Nordisk USA)
at anesthesia induction. A midline surgical approach was used starting at the
umbilicus and extending cranially once visualization of the abdominal cavity
was achieved. The pancreas was isolated, and a small section of the pancreas
(0.44 6 0.02 g) was removed from the caudal edge (distal from the
FIG. 1. Study protocol. Male vervet monkeys were administered STZ
(STZ group, n = 7) or saline (control group, n = 9). Pancreas open bi-
opsy was conducted in all monkeys 1 month after STZ was given. The
same monkeys were then euthanized 2 to 6 months after the treatment,
and the whole pancreas was collected.
TABLE 1
Baseline characteristics of the monkeys
Control
group
STZ
group
P
value
n 97
Age (years) 7.0 6 0.4 7.3 6 0.9 0.7
Body weight (kg) 7.4 6 0.3 7.0 6 0.3 0.3
Glucose (mg/dL)* 65 6 36 8 6 5 0.7
HbA1c (%) 5.0 6 0.1 5.1 6 0.1 0.5
Insulin (pmol/L)* 229 6 30 226 6 66 0.9
C-peptide (pmol/L)* 346 6 42 434 6 152 0.5
Total pancreas volume (cm
3) 6.9 6 0.7 6.5 6 0.6 0.6
Pancreas parenchymal
volume (cm
3) 5.4 6 0.5 5.2 6 0.5 0.8
*Overnight fasting.
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rapid healing. The incision was closed in three layers (linea, subcutaneous,
and skin), and monkeys were monitored postoperatively. Postoperative anal-
gesia was provided. The biopsy sample was immediately ﬁxed in neutral-
buffered 10% formalin for 24 h at 4°C and then placed into 70% alcohol for
another 24 h at 4°C before processing and embedding in parafﬁn.
Euthanasia and pancreas collection. On the day of euthanasia and pancreas
collection, insulin (or saline) treatment was administered as throughout the
study. Blood samples were collected under ketamine sedation, and then ani-
mals were euthanized via overdose with intravenous pentobarbital. The pan-
creas was immediately harvested intact, fat was trimmed, and pancreas was
weighed; then, 3- to 4-mm slices of the pancreas from tail to head (total 10
slices) were immediately ﬁxed in neutral-buffered 10% formalin for 24 h at 4°C
and placed into 70% alcohol for another 24 h at 4°C before processing and
embedding in parafﬁn.
Immunohistochemistry, immunoﬂuorescence, and morphometric analysis.
Sections of pancreas (4 mm) were stained as follows: for insulin (alkaline
phosphatase staining) and hematoxylin for b-cell mass measurements (light
microscopy); terminal deoxynucleotidyl transferase–mediated dUTP nick-end
labeling (TUNEL) and insulin for apoptosis assessment (immunoﬂuorescence);
Ki67 and insulin for assessment of proliferation (immunoﬂuorescence); with the
cocktail of antibodies for glucagon, somatostatin, and pancreatic polypeptide
and insulin (immunoﬂuorescence), and for GLUT-2 and insulin (immunoﬂuo-
rescence).
The following primary antibodies were used: guinea pig anti-insulin, 1:100
(Zymed Laboratories, San Francisco, CA); mouse antiglucagon, 1:500 (Dako,
Carpenteria, CA); mouse anti-Ki67, 1:50 (Dako); mouse antiglucose transporter
2 (GLUT2), 1:50 (R&D Systems, Minneapolis, MN); rat antisomatostatin, 1:100
(Millipore, Temecula, CA); and goat antipancreatic polypeptide, 1:100 (Novus
Biologicals, Littleton, CO). Secondary antibodies labeled with Cy3 and FITC
were obtained from Jackson Laboratories (Jackson ImmunoResearch Labo-
ratories, West Grove, PA) and used at dilutions at 1:200. For insulin alkaline
phosphatase staining, Vecstatin ABC kit from Vector Laboratories (Burlin-
game, CA) was used. For the TUNEL staining, an in situ cell death detection
kit (KIT AP; Roche Diagnostics, Indianapolis, IN) was used. Immunoﬂuores-
cence-stained sections were coverslipped with Vectashield with DAPI (nuclear
stain).
For determination of the fractional b-cell area, the entire pancreatic section
stained with insulin and hematoxylin was imaged at 403 magniﬁcation (43
objective). For the ratio of the b-cell area, the pancreas parenchymal area was
digitally quantiﬁed using Image Pro Plus software (Media Cybernetics, Silver
Spring, MD) as previously described (2). b-Cell mass was determined as
a product of the fractional pancreas parenchymal area (%) and pancreas pa-
renchymal mass (g), assuming 1 cm
3 of parenchymal volume is 1 g.
To measure individual b-cell size, 10 islets per case, stained for insulin and
hematoxylin, were selected at random and imaged at 4003 (403 objective).
b-Cell size was determined as mean individual b-cell cross-sectional area.
First, the diameter of each measured b-cell was determined. The distance from
one edge of the b-cell nucleus, across that nucleus to the nearest edge of the
adjacent b-cell nucleus, was determined using Image Pro Plus software. Next,
a similar measurement was taken, but at 90 degrees to the ﬁrst, and the mean
of the two diameters was taken as the b-cell diameter for that individual b-cell.
From this, the b-cell area was calculated using the formula Area = pr
2,a s -
suming a circular cross-sectional area. Twenty-ﬁve individual b-cell areas per
monkey were calculated.
To determine b-cell replication, sections of pancreas were double-stained
for insulin and Ki67 by immunoﬂuorescence. At least 100 islets per section
were examined, and the number of total b-cells and the number of b-cells
labeled with Ki67 were counted. The number of replicating b-cells was
expressed as a percentage of the total number of b-cells per case. In control
monkeys, we analyzed one section per monkey, but because of the smaller
number of b-cells in the STZ group, we analyzed ﬁve sections (;500 islets) per
case for euthanasia pancreas of the STZ group. A total of 28,025 b-cells in the
control group and 8,488 b-cells in the STZ group were counted.
To determine the frequency of b-cell apoptosis, we double-stained sections
for insulin and TUNEL by immunoﬂuorescence and analyzed a minimum of
100 islets per section. The number of total b-cells and the number of TUNEL-
labeled b-cells were quantiﬁed. Because of the low frequency of apoptosis, we
quantiﬁed TUNEL in ﬁve sections per control case and 5–10 sections per STZ
case. The number of apoptotic b-cells was expressed as a percentage of the
total number of b-cells per case. A total of 127,570 b-cells in the control group
and 19,634 b-cells in the STZ group were examined. The number of b-cells
evaluated in each individual monkey is reported in Supplementary Table 1.
Calculations of b-cell turnover. b-Cell turnover was established applying
the model proposed recently (18). The model described b-cell mass as the
balance between b-cell formation (either by b-cell replication or by other
sources of b-cells) and loss (through b-cell apoptosis or necrosis):
dMðtÞ
dt
¼ RR

t

2RA

t

þ OSB

t

ð1Þ
where dM(t)/dt [mg/month] is the mass derivative, i.e., rate of change in b-cell
mass, M(t) [mg]; RR(t) [mg/month] and RA(t) [mg/month] are, respectively,
rates of b-cell replication and apoptosis derived from frequencies of b-cell
replication and apoptosis (fraction of replicated [apoptotic] b-cells) each
multiplied by the respective conversion factors (26) and by b-cell mass; OSB
(t) [mg/month] indicates the contribution of other sources of b-cells, i.e., from
sources different from b-cell replication, to b-cell mass. Conversion factors for
b-cell replication and apoptosis were assumed to be the same as in rats (26).
At steady state, i.e., dM(t)/dt = 0 and the rates are time-independent, that is,
RR(t)=RR, RA(t)=RA,a n dOSB(t)=OSB, Eq. (1) becomes:
OSB ¼ 2RR þ RA ð2Þ
Statistical analysis. Data are presented as mean 6 SEM. Statistical com-
parisons were carried out using the Student t test with a P value , 0.05 taken
as signiﬁcant. A simple regression was carried out for the correlation analysis.
RESULTS
Induction of diabetes. Before STZ treatment, fasting
plasma glucose levels were comparable in control and STZ
groups (65 6 3 vs. 68 6 5 mg/dL, control vs. STZ groups,
P = 0.7, Table 1). Two days after STZ injection, all monkeys
FIG. 2. A: There was no difference in pancreas parenchymal volume
measured by CT scan between control (n = 9) and STZ (n = 7) groups at
baseline, and no change in pancreas parenchymal volume was seen
during the study. All 16 animals had CT scans to quantify pancreas
parenchymal volume on all three occasions (for details, see RESEARCH
DESIGN AND METHODS)( a l lP > 0.4). B: There was a good correlation be-
tween mean pancreas parenchymal volume and pancreas weight (r
2 =
0.82, P < 0.0001), and the ﬁnal pancreas parenchymal volume and
pancreas weight (r
2 = 0.5, P < 0.01).
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and they remained diabetic throughout the study (Fig. 3A).
As anticipated, HbA1c was increased in the STZ versus
control group (8.2 6 0.3 vs. 4.9 6 0.1%, 1 month after STZ
or saline, P , 0.0001, Fig. 3B). Body weight remained
comparable during the study in control and STZ groups
(Fig. 3C).
IVGTT data. Glucose, insulin, and C-peptide concen-
trations during baseline IVGTT and IVGTT plus arginine
before biopsy and euthanasia are shown in Fig. 4 and
Table 2. At baseline IVGTT, glucose levels were similar in
the two groups, but, as expected, they were signiﬁcantly
higher (P , 0.01) in monkeys given STZ during the
two following IVGTTs (Fig. 4A). Insulin and C-peptide
concentrations were comparable in controls and monkeys
given STZ at baseline, whereas they were almost zero after
STZ treatment even after the arginine infusion (Fig. 4B and
C), thus preventing the use of minimal models to quantify
b-cell function and insulin sensitivity in monkeys given
STZ.
b-Cell function and insulin sensitivity. Indices of b-cell
function and insulin sensitivity are shown in Table 2.
During baseline IVGTT, parameters were comparable in
controls and monkeys given STZ. After STZ treatment, the
fasting insulin and C-peptide concentrations were at or
near the limit of detection so that F1, F2, and SI were not
distinguishable from zero.
b-Cell mass. b-Cell mass remained comparable in the
control group during the 5-month period of observation
(93 6 17 vs. 89 6 9 mg, biopsy vs. euthanasia, Fig. 5). As
expected, the STZ group had a marked (;90%) deﬁcit in
FIG. 3. Fasting plasma glucose (A), HbA1c levels (B), and body weight
(C) during the study. One month after the treatment, all monkeys in
the STZ group developed severe diabetes, and this marked hypergly-
cemia remained during the study (A and B). There was no signiﬁcant
change in body weight during the study in both control and STZ groups
(C). *P < 0.01 vs. control.
FIG. 4. Plasma glucose (A), insulin (B), and C-peptide (C) concen-
trations during IVGTT followed by arginine (t = 30 min) 1 month after
STZ or saline treatment. The marked deﬁcit in insulin secretion in re-
sponse to glucose and arginine after STZ is consistent with the ;90%
deﬁcit in b-cell mass induced by STZ (Fig. 5).
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vs. control, P , 0.001), the deﬁcit being stable during the
subsequent 5 months (Fig. 5). No difference was found
between the mean individual b-cell size in controls versus
monkeys given STZ (108 6 2 vs. 101 6 5 mm
2, P = ns).
There was also no apparent difference in the distribution
of small islets around ducts or scattered b-cells in the
monkeys given STZ compared with controls. The residual
b-cells in the islets were found mainly in relatively b-cell–
depleted islets rather than as increased numbers of small
aggregates.
b-Cell replication and apoptosis. Consistent with adult
humans, the frequency of detected b-cell replication was
very low in control monkeys (0.050 6 0.023%) (Fig. 6A).
TABLE 2
Responsivity to glucose of ﬁrst phase (F1), second phase (F2), basal insulin secretion (Fb), insulin sensitivity (SI), and glucose
effectiveness (SG) in controls and monkeys administered STZ at baseline, biopsy, and euthanasia studies
Control group STZ group
Baseline Biopsy Euthanasia Baseline Biopsy Euthanasia
F1 [10
9] 125 6 29 289 6 66+ 145 6 43 107 6 30 0 6 0*+ 0 6 0*†
F2 [10
9 min
21]8 6 39 6 44 6 37 6 60 6 00 6 0
Fb [10
9 min
21] 6.4 6 0.9 9.3 6 1.9 5.2 6 1.1¶ 8.4 6 2.3 0.8 6 0.2*+ 0.8 6 0.3*†
SI [10
24 L pmol
21 min
21] 1.4 6 0.2 1.6 6 0.4 1.3 6 0.5 1.9 6 0.6 0 6 0*+ 0 6 0*†
SG [min
21] 2.5 6 0.2 2.5 6 0.3 2.2 6 0.2 2.7 6 0.4 2.7 6 0.2 2.7 6 0.3
*Control vs. STZ, P , 0.05. +Baseline vs. biopsy, P , 0.05. †Baseline vs. euthanasia, P , 0.05. ¶Biopsy vs. euthanasia, P , 0.05.
FIG. 5. A: Islet morphology of control (a–d) and STZ (e–h) groups. As expected, there was no change in islet morphology between biopsy and
euthanasia pancreas in control group. In contrast, there was a marked reduction in the number of b-cells per islet in STZ group at biopsy and
euthanasia. B: b-Cell mass during the study. The b-cell mass was ;90% decreased at biopsy (1 month after the treatment) in the STZ group
compared with that of the control group. This decreased b-cell mass did not recover during the study. Glu, glucagon; Ins, insulin. (A high-quality
digital representation of this ﬁgure is available in the online issue.)
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response to the b-cell deﬁcit induced by STZ during the
sampling interval (0.050 6 0.023 and 0.013 6 0.008%, P =
0.2 control vs. STZ at euthanasia) (Fig. 6A). Also consistent
with adult humans, the frequency of b-cell apoptosis was
very low in the control monkeys (0.013 6 0.003%). The
frequency of b-cell apoptosis did not appear to be inﬂu-
enced by the glucose concentrations of ;300–400 mg/dL
in the monkeys given STZ because we did not ﬁnd any
TUNEL-positive b-cells in the pancreas of monkeys given
STZ.
b-Cell turnover. Having established that b-cell mass,
replication, and apoptosis were at steady state over the
period of observation, we applied the model to compute
b-cell turnover to the euthanasia samples where the sam-
ple size was much larger than from the biopsy sample. This
analysis revealed ongoing b-cell turnover in adult non-
human primates (3.3 6 0.9 mg/month, Fig. 7).
In control monkeys, the measured rate of b-cell apo-
ptosis (3.3 6 0.9 mg/month) exceeded the measured rate
of b-cell replication (0.7 6 0.3 mg/month), implying that
for steady-state b-cell mass to prevail, the majority of
newly forming b-cells are derived independently of b-cell
replication, i.e., from b-cell neogenesis (2.6 6 0.8 mg/
month) (Fig. 7A). In a similar manner, we also assessed
b-cell turnover by adapting the model to compute the
turnover of b-cell number rather than mass. The rates of
b-cell apoptosis and replication were (3.9 6 1.0) $ 10
6 and
(0.9 6 0.4) $ 10
6 b-cells per month, with a computed rate of
neogenesis of (3.0 6 1.0) $ 10
6 b-cells per month. By use of
this approach, the computed fractional rate of b-cell
turnover in control monkeys was ;4% b-cells per month.
Given the low frequency of b-cell apoptosis events in
monkeys administered STZ, we were unable to securely
use the model in this group, but simply note the lack of an
adaptive increase in b-cell mass or b-cell replication (vide
supra) implying lack of a meaningful adaptive increase in
b-cell regeneration.
GLUT2 in b-cells and other endocrine cell types. Be-
cause we found no evidence of hyperglycemia-induced
FIG. 6. Frequency of b-cell replication (A) and apoptosis (B) in control and STZ groups. Despite the marked hyperglycemia, no increase in fre-
quency of b-cell apoptosis was observed in the STZ group compared with the control group (B). GLUT2 staining did not reveal degranulated b-cells
(i.e., insulin-negative GLUT2-positive islet cells); however, in the STZ group, GLUT2 immunoreactivity was decreased in cell membranes and
increased in cytoplasm of b-cells (C). When examining islets for insulin immunoreactivity (green) and glucagon, somatostatin and pancreatic
polypeptide combined (red), all endocrine cells in islets in both controls and monkeys given STZ were accounted for (D). (A high-quality digital
representation of this ﬁgure is available in the online issue.)
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distribution of GLUT2 protein in pancreatic sections of
STZ and control pancreas were evaluated. As expected, in
control samples GLUT2 immunoreactivity was abundant in
the membrane of b-cells (Fig. 6C). In contrast, GLUT2
immunoreactivity was decreased in membranes of b-cells
in monkeys given STZ (Fig. 6C). We did not identify islet
cells expressing GLUT2 that did not stain for insulin in
either control or STZ pancreas, suggesting that degranu-
lated b-cells were not present in detectable numbers in
either controls or monkeys given STZ. This conclusion was
supported by immunostaining for insulin and a mixture of
antibodies against glucagon, somatostatin, and pancreatic
polypeptide that collectively accounted for the remaining
endocrine cells in the islets of monkeys given STZ (Fig. 6D).
DISCUSSION
We report that b-cell turnover continues in adult non-
human primates, with newly formed b-cells derived pri-
marily from sources of b-cells independent of duplication of
existing b-cells, deﬁned as such here as b-cell neogenesis.
However, we found no evidence of increased b-cell turn-
over in an STZ model of type 1 diabetes.
Measurement of b-cell turnover by a model-based ap-
proach was used in this study in nonhuman primates
because lineage tracing is not readily accomplished in
primates. The attributes and limitations of the model have
been discussed in detail (18). Conversion of the frequency
of b-cell replication and apoptosis to the respective rates
of replication and apoptosis was accomplished by con-
version factors developed by a combination of in vivo time
lapse imaging and subsequent immunohistochemistry (26).
These conversion factors were developed in rat islets and
to the extent that they differ in nonhuman primates, the
current study may be in error. Given the low frequency of
both b-cell apoptosis and replication, relatively large
errors in quantiﬁcation of b-cell turnover may arise unless
a substantial number of cells are evaluated. To this end, we
quantiﬁed b-cell replication and apoptosis in ;36,500 and
;147,000 b-cells, respectively.
We deﬁne b-cell neogenesis in this study as b-cells
arising from sources other than replication detected by
Ki67 in insulin-positive b-cells. One possible source of
b-cell neogenesis using this deﬁnition would be duplica-
tion of degranulated b-cells that were not detected by
insulin immunostaining. Also, if b-cells dedifferentiated
and lost insulin immunoreactivity before duplication, by
this deﬁnition these cells would be considered as arising
from neogenesis. In the absence of lineage tracing in
nonhuman primates, we cannot fully exclude either of
these possible sources of b-cells. However, we were able
to account for the endocrine cells in monkeys given STZ
by immunostaining for a combination of insulin, glucagon,
somatostatin, and pancreatic polypeptide. Although some
b-cells did have less intense immunoﬂuorescence for in-
sulin in monkeys given STZ versus controls consistent with
some degree of insulin degranulation, they were still de-
tectable. A similar pattern is present in patients with type 1
diabetes who have b-cells still present, whereas complete
loss of insulin immunoreactivity has been reported in ap-
parent b-cells in some rodent models of diabetes (27).
Ideally to model changes in b-cell turnover, multiple
measurements of b-cell mass and turnover would be ac-
quired in the same individuals at different time points.
Because it is currently not possible to quantify b-cell mass
or b-cell turnover noninvasively, we elected to obtain two
samples of pancreas from the same individual on two
occasions, ﬁrst by surgical open biopsy and the second at
euthanasia. The time between the ﬁrst and second samples
was varied between individuals as illustrated in Fig. 1 to
permit a range of measures of b-cell mass and turnover
after acute induction of a deﬁcit in b-cell mass by STZ.
As expected, in the control group, there was no change
in b-cell mass during the study period. Also the frequency
of b-cell replication (by Ki67) and apoptosis (by TUNEL)
were comparable in control pancreas secured by the
samples at various time points during the study, implying
steady-state b-cell turnover. Given the greater sample size
available when the pancreas was resected at euthanasia,
we focused on this sample to evaluate b-cell turnover. The
results of that analysis imply that b-cell mass is renewed
and sustained by ongoing b-cell turnover in nonhuman
primates, with a fractional b-cell turnover of ;4% per
month, implying a b-cell average life span of ;3 years.
Consistent with recent data in the adult rat using the same
model (18), the majority of new b-cell formation in adult
nonhuman primates is derived independently of replica-
tion of existing b-cells, deﬁned as such in this article as
b-cell neogenesis. However, the extent of ongoing b-cell
turnover in nonhuman primates quantiﬁed here is much
less than found in the rat. Recent lineage tracing data
implying b-cell neogenesis from ductal precursors in mice
are supported by present ﬁndings (28). After documenting
and quantifying b-cell turnover in adult nonhuman pri-
mates, our secondary goal was to establish whether b-cell
turnover is sustained in an STZ model of type 1 diabetes.
Moreover, we sought to establish whether there was any
evidence of an adaptive increase in b-cell formation in
response to b-cell deﬁciency and diabetes in this model.
The deﬁcit in b-cell mass in the monkeys given STZ was
comparable to that in established type 1 diabetes in
humans (1,3). To accomplish effective b-cell regeneration
in the STZ nonhuman primate model, b-cell formation
would need to be adaptively increased to a rate that
exceeds loss of b-cells through normal aging. However,
there was no increase in b-cell mass or amelioration of
diabetes in the adult nonhuman primates during the 6
months after induction of diabetes. There was no increase
in b-cell replication in monkeys given STZ compared with
the control monkeys. Given the absence of a recordable
frequency of b-cell apoptosis in monkeys given STZ, we
FIG. 7. b-Cell turnover in control group, showing the relative con-
tributions of b-cell replication, formation of b-cells from other sources
than replication (neogenesis), and b-cell apoptosis. In controls there
was a minimal change in b-cell mass during the study, but the mathe-
matic model revealed active b-cell turnover with the major contribution
being from neogenesis rather than b-cell replication. In the absence of
measurable apoptosis in monkeys given STZ, b-cell turnover could not
be reliably computed, but given the absence of any change in b-cell
mass, b-cell turnover can reasonably be assumed to not be adaptively
increased to a clinically meaningful extent.
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therefore neogenesis, under these conditions. However,
given the lack of an increment in b-cell mass in monkeys
studied twice over time after STZ, and the rarity of b-cell
apoptosis, it can be reasonably surmised that any adaptive
increase in b-cell neogenesis in response to diabetes in this
model was trivial.
These data are consistent with available data in humans
with established type 1 diabetes in whom a low number of
b-cells are often still detected, with minimal b-cell repli-
cation and a detectable but low frequency of b-cell apo-
ptosis (3,29). We previously proposed that the latter
implies ongoing b-cell formation, but presumably at a rate
that is insufﬁcient to accomplish b-cell regeneration (a net
increase in b-cell mass), a conclusion that has recently
gained independent support (29). In either type 1 diabetes
or the nonhuman primate administered STZ, effective
b-cell regeneration would require formation of new b-cells
at a rate that exceeds natural attrition. It is unclear to what
extent b-cell neogenesis can adaptively increase, and if so
how it is regulated. In a rat model of type 2 diabetes, we
observed a marked increase in b-cell neogenesis that
delayed loss of b-cell mass in response to a shortened
b-cell life span through increased apoptosis (18). The lack
of an adaptive increased rate of b-cell neogenesis in non-
human primates compared with rats might be a species
difference. Another possibility is that STZ induces toxicity
in the precursor cells that give rise to b-cell neogenesis.
Alternatively, the high glucose values present in this study
may have constrained effective new b-cell formation. In
a prior study of individuals with long-standing type 1 di-
abetes, we did observe more residual b-cells in those
individuals with better glycemic control before death, al-
though it is plausible that the better control was due to
residual insulin secretion (3). Notably, in the current study
we deliberately included adult monkeys, whereas most
studies of b-cell regeneration have been undertaken in
juvenile rodents with a much higher capacity for new
b-cell formation (19).
The absence of increased b-cell apoptosis in the non-
human primate administered STZ exposed to glucose val-
ues of ;300–400 mg/dL for up to 6 months is in contrast
with the reported actions of high glucose concentrations
to induce increased b-cell apoptosis (30). However, most
studies that report actions of high glucose concentrations
to induce b-cell apoptosis have been undertaken in animal
models with other mechanisms of b-cell toxicity present or
in isolated islets that have a high rate of b-cell apoptosis
consequent upon anoxia. In the current study, we noted
that plasma membrane localization of GLUT2 transporter
protein in b-cells of STZ nonhuman primates was de-
creased, consistent with prior reports in rodents with di-
abetes (31–33). Thus, it is likely that b-cells adaptively
protect themselves from long-term glucose toxicity by
decreasing access of glucose to the b-cell. Of course, this
in turn would likely compound impaired b-cell function
(34,35). In a recent study that examined the actions of
comparable glucose concentrations on the islet in vivo in
rats, there was no increase in b-cell apoptosis, but rather an
adaptive increase in b-cell replication and mass in response
to hyperglycemia (36). Collectively these studies imply that
in vivo glucotoxicity may act more through its actions to
impair b-cell function than induce b-cell apoptosis.
In conclusion, we report that b-cell turnover is present
in adult nonhuman primates with the predominant source
of new b-cells being derived from a source independent of
duplication of existing differentiated b-cells. The rate of
b-cell turnover in adult nonhuman primates is much
slower than in rodents, consistent with the reported long
life span of b-cells in humans (37,38). There was no mea-
surable adaptive increase in b-cell mass or formation in
STZ-induced diabetes in nonhuman primates, again in
contrast with the regeneration reported in young rodents.
The failure of b-cell regeneration after a single dose of STZ
in nonhuman primates mirrors that in humans with
established type 1 diabetes. The STZ monkey model may
represent a more clinically relevant model to test strategies
to foster b-cell regeneration in type 1 diabetes than rodents
administered STZ. Given the possible importance of on-
going local cytokines on fostering stem cell recruitment,
ideally a model with spontaneous autoimmune-mediated
b-cell destruction in a primate would be available for such
investigations.
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